Brief: Delcath Systems Announces FDA Approval Of HEPZATO KIT for The Treatment Of Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
15/08/2023 02:13
Aug 14 (Reuters) - Delcath Systems Inc DCTH.O :
* DELCATH SYSTEMS, INC. ANNOUNCES FDA APPROVAL OF HEPZATO
KIT™ FOR
THE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE
HEPATIC-DOMINANT METASTATIC UVEAL MELANOMA
* : APPROVAL INCLUDES TREATMENT NAÏVE AND PREVIOUSLY TREATED
PATIENTS AND IS NOT LIMITED BY HLA GENOTYPE
* CO PLANS TO HAVE COMMERCIAL PRODUCT AVAILABLE IN Q4
Source text for Eikon: ID:nPncgsRpga
Further company coverage: DCTH.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Delcath Systems Q1 revenue beats on Hepzato growth
Brief: Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology
Delcath Q4 revenue rises 37%, beats estimates
Brief: Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)